TG and Rhizen to co-develop PI3K inhibitor
This article was originally published in Scrip
Executive Summary
New York-based TG Therapeutics has licensed a phosphoinositide-3-kinase (PI3K) inhibitor of the delta pathway from Rhizen Pharmaceuticals of Switzerland that it hopes to position as one of the first PI3K therapies on the market for haematological malignancies and autoimmune disorders.
You may also be interested in...
Alembic Remains Upbeat Despite Rhizen Setback
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has 15-plus launches lined up.
Setback For Alembic-backed Rhizen After Concerns Over PI3K Inhibitors
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has15-plus launches lined up.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.